Tissue Localized Inhibition of Complement Activation
Time: 4:40 pm
day: Track A - Day 3PM
- Delivery of targeted bispecific fusion proteins are intended to drive a high local concentration of complement inhibitors in the tissue while reducing systemic complement blockade
- Bispecific fusion proteins were designed, expressed, and characterized in vitro to show modulation of complement activation over a broad potency range.
- In vivo studies in rodent preclinical models demonstrate targeting-dependent distribution and durable inhibition of complement activation in disease tissues
- These data demonstrate the potential to address autoimmune and inflammatory diseases that are driven by dysregulation of complement